📅 PUBMED DAILY TRIAGE — 2026-04-25

Window: 2026-04-24T09:00:00Z → 2026-04-25T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~85 candidates | Candidates evaluated (scored): 15 High priority: 1 | Standard: 11 | Low/archive: 3 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (ctDNA / cfDNA / Liquid Biopsy)

TR-2026-04-25-001 / PMID 42028006 · Pan-cancer differentially methylated regions are promising biomarkers for non-invasive diagnosis in multiple cancers · 8/10 🔴

Pan-cancer DMR cfDNA methylation model validated in n=1,108 across 7 cancer types achieves 77% sensitivity / 96.9% specificity, with stage I/II detection ≥69% — the pan-DMR approach across 11 malignancies represents a more scalable multi-cancer liquid biopsy strategy than type-specific markers. (iScience | Zhu Z et al. | DOI: 10.1016/j.isci.2026.115425 | PMC open access)

Topics with zero HIGH-priority articles today:

• Hematologic malignancies: No 8+ articles (best candidate scored 6/10)
• AI/ML diagnostics & imaging: No 8+ articles (best candidate scored 7/10)
• Novel therapeutics (immunotherapy/CAR-T/targeted): No 8+ articles (best candidate scored 7/10)
• CBC-based diagnostics and ML in hematology: No 8+ articles (best candidate scored 0/10 — topic sparse, no human CBC-ML hits this window)
• Precision oncology / genomic medicine: No 8+ articles (best candidate scored 6/10)
• Cardiovascular-metabolic (GLP-1/SGLT2/cardiometabolic): No 8+ articles (best candidate scored 6/10)
• Aging, longevity, and population health: No 8+ articles (best candidate scored 6/10)
• Rare diseases with high unmet need: No 8+ articles (best candidate scored 6/10)

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

• TR-2026-04-25-005 / 42032313 · Longitudinal localization of leukaemic stem cells between metaphysis and central marrow governs their behaviour · 5/10 · Drug Development (preclinical) — Nature Cell Biology. DPP4-CXCL12-GPC3 axis controls AML LSC niche protection; targeting DPP4 displaces LSCs and sensitizes to chemo in murine models. Clinical DPP4 inhibitors exist.
• TR-2026-04-25-006 / 42032308 · MDS/MPN patients have higher post-allo-HCT relapse rates vs MDS: SBTMO/CIBMTR registry · 6/10 · Treatment Innovation — Multi-center Brazilian registry. Clinically actionable: MDS/MPN overlap warrants distinct transplant strategy.
• TR-2026-04-25-013 / 42027619 · Role of Genomics in Development and Treatment of Multiple Myeloma · 4/10 · Genomics/Precision Medicine (Review)

Early Cancer Detection (ctDNA / cfDNA / Liquid Biopsy)

• TR-2026-04-25-003 / 42027134 · CRISPR/Cas12a + quantum dots for ctDNA PIK3CA E542K in breast cancer plasma · 7/10 · Diagnostics — 100% specificity / AUC 0.978 for staging in 42 clinical plasma samples. Attomolar sensitivity in 30 min. Promising but requires larger validation.
• TR-2026-04-25-012 / 42027143 · Metal-isotopic suspension array for high-throughput liquid biopsy diagnostics (review) · 5/10 · Diagnostics (technology review)

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-04-25-004 / 42031964 · Deep learning for predicting pituitary neuroendocrine tumour lineage and subtypes from H&E · 7/10 · Diagnostics — Multicenter (n=1,344): AUC 0.912 for lineage classification, externally validated. H&E-based; near-term implementable with spatial transcriptomics mechanistic support.
• TR-2026-04-25-008 / 42032039 · DeepDrugDiscovery: AI identifies BBB-permeable autophagy enhancers for Alzheimer's · 6/10 · Drug Development — Nature Biomedical Engineering. mTOR-independent BBB-permeable leads clear AD aggregates and restore memory in worm+mouse models. Open-source platform released.
• TR-2026-04-25-010 / 42023444 · ML models for postop depression risk prediction in ovarian cancer (n=850) · 5/10 · Diagnostics/Mental Health — RF AUC 0.776; resolved from deferred 2026-04-24 run.

Novel Therapeutics (Immunotherapy / CAR-T / Targeted)

• TR-2026-04-25-002 / 42032342 · Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment (review) · 7/10 · Treatment Innovation — Nature Cancer. Synthesizes TME reprogramming from clinical trials; identifies barriers to durable responses.

Cardiovascular-Metabolic

• TR-2026-04-25-007 / 42032277 · Nocturnal hypertension reclassifies risk in white-coat hypertension during pregnancy (n=991) · 6/10 · Diagnostics — WCH with nocturnal HTN: OR 11.95 for preeclampsia, comparable to sustained HTN. Supports routine ABPM including nighttime BP in pregnancy.

Aging, Longevity, and Population Health

• TR-2026-04-25-011 / 42032757 · Senescence of T cells and organ aging (review) · 5/10 · Prevention — Covers PD-1 blockade, senolytic CAR-T, mTOR inhibition and MSC therapy as emerging anti-immunosenescence strategies.

Rare Diseases / Precision Oncology / Genomics

• TR-2026-04-25-009 / 42031741 · RPS4X variants cause X-linked intellectual disability with microcephaly and autism · 6/10 · Genomics — NPJ Genomic Medicine. 6 patients across multiple cohorts (incl. 100,000 Genomes Project). Novel XLID gene; functional validation in fibroblasts and zebrafish.

💡 UNSOLICITED FINDS

None this run. Sentinel scan (209 raw results) did not produce additional high-signal out-of-watchlist articles beyond those already captured under watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 3 | Diagnostics: 5 | Treatment Innovation: 2 | Drug Development: 2 | Prevention: 1 | Genomics/Precision Medicine: 1 | Public Health: 1

By evidence maturity:

• Exploratory: 8 | Validated: 5 | Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 15 | preprint: 0

Topics with zero HIGH-priority articles this run: All except Early Cancer Detection.

CBC/ML hematology topic: Zero relevant human hematology hits this window — top CRDT results were animal genomic prediction papers. No human CBC-ML papers entered this window. Will monitor next run.

🔧 RUN NOTES

• Window expansion: NOT triggered. 15 relevant records found across topics (well above threshold of 5).
• Truncation: AI/ML diagnostics topic (175 raw) and Aging/longevity (245 raw) truncated at 10 cap. Top candidates from each reviewed — all strong candidates captured.
• CBC/ML hematology topic zero-hit: This is the second consecutive run with sparse CBC-specific ML results in the CRDT window. Topic query may need broadening for next run.
• Deferred PMID resolved: 42023444 (ML postop depression, ovarian cancer) successfully retrieved; classified as STANDARD, score 5.
• Partial failures: None. All 9 topic searches and 1 sentinel search completed successfully.
• Rolling 7-day zero-HIGH topics: CBC/ML hematology (consistently sparse). All other topics produced ≥1 HIGH in the past week except today.
• Nature journal cluster today: 3 articles in top journals (Nature Cell Biology, Nature Cancer, Nature Biomedical Engineering) — all scored STANDARD due to preclinical/review design constraints.